Literature DB >> 15330158

Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines.

Frank Riedel1, Karl Götte, Ulrich Goessler, Hannen Sadick, Karl Hörmann.   

Abstract

BACKGROUND: Angiogenesis is increased in various human cancers, including head and neck squamous cell carcinoma (HNSCC), and correlates with tumour progression and metastasis. Vascular endothelial growth factor (VEGF) has been shown to be a key regulator of angiogenesis. Tumour treatment with anticancer agents might have an effect on the secretion of VEGF. Therefore, we determined whether certain chemotherapeutic agents stimulate VEGF secretion in HNSCC and whether VEGF antisense oligonucleotide treatment can modulate these effects in vitro.
MATERIALS AND METHODS: The effect of chemotherapeutic agents (Cisplatin, Carboplatin and 5-FU) on the production of VEGF was investigated on established human HNSCC cell lines at both mRNA and protein levels. By using a 21-mer VEGF antisense phosphorothioate oligonucleotide targeting the translation start site of human VEGF mRNA, we examined modulation of VEGF expression in cell line supernatants by capture ELISA.
RESULTS: The treatment of HNSCC cell lines with chemotherapeutic agents resulted in a significant induction of VEGF production. Carboplatin most prominently induced the release of VEGF from the tumour cells. VEGF antisense oligonucleotide treatment resulted in a significant reduction of chemotherapy-induced VEGF up-regulation compared to sense control.
CONCLUSION: Induction of VEGF secretion might contribute to the frequently observed drug resistance of HNSCC to chemotherapeutic agents. This molecular effect might be reduced by the use of VEGF antisense oligonucleotides in head and neck cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330158

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.

Authors:  Lisa D Volk; Michael J Flister; Deena Chihade; Neil Desai; Vuong Trieu; Sophia Ran
Journal:  Neoplasia       Date:  2011-04       Impact factor: 5.715

2.  Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.

Authors:  P Hamberg; N Steeghs; W J Loos; D van de Biessen; M den Hollander; M Tascilar; J Verweij; H Gelderblom; S Sleijfer
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

3.  Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.

Authors:  Francesco Di Costanzo; Silvia Gasperoni; Virginia Rotella; Federica Di Costanzo
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

4.  Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

Authors:  Lisa D Volk; Michael J Flister; Christopher M Bivens; Alan Stutzman; Neil Desai; Vuong Trieu; Sophia Ran
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

5.  TNFR-1 on tumor cells contributes to the sensitivity of fibrosarcoma to chemotherapy.

Authors:  Jingjing Deng; Xiaopu Zhao; Lijie Rong; Xiao Li; Xiaoman Liu; Zhihai Qin
Journal:  Protein Cell       Date:  2013-04-30       Impact factor: 14.870

6.  Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.

Authors:  Yu-Quan Xiong; Hui-Chuan Sun; Xiao-Dong Zhu; Wei Zhang; Peng-Yuan Zhuang; Ju-Bo Zhang; Hua-Xiang Xu; Ling-Qun Kong; Wei-Zhong Wu; Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-21       Impact factor: 4.553

Review 7.  Nanoparticle-based targeted therapeutics in head-and-neck cancer.

Authors:  Ting-Ting Wu; Shui-Hong Zhou
Journal:  Int J Med Sci       Date:  2015-01-12       Impact factor: 3.738

Review 8.  Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.

Authors:  Bao T Le; Prithi Raguraman; Tamer R Kosbar; Susan Fletcher; Steve D Wilton; Rakesh N Veedu
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.